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Abstract 
Background: Allergic rhinitis affects 10–30 % of the global population and this number is likely to increase in the 
forthcoming years. Moreover, it commonly co‑exists with allergic asthma as a chronic allergic respiratory syndrome. 
While the involvement of Th2 cells in allergy is well understood, alterations of pro‑inflammatory Th17 responses remain 
poorly characterized. The aim of our study was to determine whether natural seasonal allergen exposure causes 
changes in T cell subset characteristics in patients with allergic rhinitis and asthma.
Methods: Sixteen patients with allergic rhinitis/atopic asthma (9M, 7F; age 31.8 ± 12.1) and 16 healthy controls were 
recruited into the study (9M, 7F; age 31.2 ± 5.3). Blood samples were collected from the patients 1–3 months before 
pollen season (visit 1), within 7 days of the appearance of pollen/initiation of allergic symptoms (visit 2) and 2 weeks 
after visit 2 following the introduction of symptomatic treatment with antihistamines (visit 3). Flow cytometry was 
used to assess major T cell subsets (naïve, central memory, effector memory and CD45RA+ effector) and key T cell 
cytokine production (IFNγ, IL‑17A, TNF and IL‑4) using intracellular staining. Data were analyzed using repeated meas‑
ures ANOVA and paired t test.
Results: As expected, an increase in the percentage of IL‐4+ CD4+ cells was observed during natural pollen 
exposure in patients with allergic respiratory syndrome. No significant changes were observed in the production of 
other cytokines, including Th17 cells, which tended to be lower than in the control population but unchanged during 
pollen exposure. Introduction of antihistamine treatment led to only moderate changes in cytokine production from 
CD4 and CD8 T cells. Selective changes in CD8+ T cells were observed during natural pollen exposure including a 
decrease in transient cells (with features of CD45RA+ and CD45RO+ cells) and a decrease in the percentage of cen‑
tral memory cells in the peripheral circulation. Within the CD4 cell group the total percentage of CD45RA positive CD4 
cells was increased during pollen exposure.
Conclusions: Th1 and Th17 responses are not altered during pollen season but allergen exposure affects T cell activa‑
tion and memory cell status in patients with allergic respiratory syndrome.
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Background
Allergic rhinitis affects 10–30 % of the global population 
[1] and it seems that economic growth and industriali-
zation will only serve to increase this number, not only 
due to changes in the living environment [2], but also 
due to expansion of allergic plants caused by increased 
carbon dioxide concentration in the air [3]. In the Pol-
ish population, clinicians diagnose allergic rhinitis in 
30.6 % of adults. Among Polish young adults, 16.7 % suf-
fer from seasonal allergic rhinitis [4], which is most fre-
quently caused by allergens such as pollens from trees 
and grass.
Symptoms of allergic rhinitis and allergic asthma often 
coexist and it is postulated that they represent a response 
to the same allergen from upper and lower airways, 
together named chronic allergic respiratory syndrome 
[5]. The same inflammatory response is observed in nasal 
mucosa of patients with allergic rhinitis and bronchial 
mucosa of patients with asthma. In both of these situa-
tions, infiltration by Th2 cells is present [5].
Allergen presentation causes differentiation of T cells 
into Th2 cells, which produce cytokines stimulating B 
cells to produce IgE antibodies. These antibodies bind 
to mast cells and allergens causing a release of media-
tors, such as histamine, which are responsible for the 
symptoms of allergic rhinitis. T cells also take part in the 
recruitment of eosinophils into the inflammatory site and 
development of the late phase of allergic reaction [6]. In 
the allergic reaction Th17 may also play a significant role 
[7]. Although an increased serum level of IL-17 in aller-
gic patients has been described in many studies [8, 9], 
less is known about changes in Th17 cells caused by natu-
ral seasonal allergen exposure. Systemic reaction caused 
by contact with allergen has been widely investigated in 
many studies, however, the immunological mechanisms 
leading to primary and secondary responses still remain 
unclear.
T cells appear to be strongly involved in this process 
and its subsets may differ depending on antigen stimula-
tion. The CD45RA marker is characteristic for naïve cells, 
which proliferate when stimulated with antigens, while 
the presence of CD45RO is characteristic for memory 
cells, which proliferate during re-call antigen stimula-
tion [10]. Expression of C–C chemokine receptor type 7 
(CCR7, CD197) on memory T cells enables distinguish-
ing of central memory T cells (CD45RA− CCR7+), 
which are able to migrate to the lymph nodes and 
stimulate dendritic cells, from effector memory T cells 
(CD45RA− CCR7−), which possess effector functions 
and can migrate to the inflammatory site [11]. Transcrip-
tional activation of dendritic cells caused by interaction 
with memory T cells and increased T cell proliferation 
after culturing with allergen-stimulated dendritic cells 
in patients suffering from allergic rhinitis has been 
described by Larsson et al. [12]. After secondary stimu-
lation, central memory T cells lose their CCR7 receptor 
and acquire effector function becoming effector memory 
T cells [11].
Although a primary study [11] described the pres-
ence of a CD45RA+ effector cell population (CD45RA+ 
CCR7−) of CD8 cells and lack of this population among 
a pool of CD4 cells, a newer study revealed the presence 
of a CD4+ CD45RA+ CCR7− population, which is the 
most differentiated type [13]. It has been shown that per-
centages of these cell subsets may differ depending on 
antigen persistence and load [13].
Allergen-specific naïve and memory T cells differ in 
allergic and in healthy patients [14]. Changes are also 
observed depending on whether stimulation is caused 
by perennial or seasonal allergen. Dust mite-specific 
cells from mite-allergic patients are mostly of the cen-
tral memory phenotype, while specific T cells from birch 
pollen-allergic patients have features of effector memory 
cells [15].
Several studies have described changes of CD45RO/
RA cells in patients with seasonal allergies [16–19], how-
ever, less is known about changes in central memory and 
effector memory cell subsets in these patients. In particu-
lar, studies describing the changes caused by pollen expo-
sure in T cell subpopulations of patients suffering from 
allergic rhinitis are required. Interestingly, expression of 
surface antigens CCR4, CXCR1 and CD62L on memory 
cells increases during pollen season only in sympto-
matic atopic patients, explaining the lack of symptoms 
in patients with asymptomatic skin sensitization and 
healthy controls [20].
The aim of our study was to determine whether natural 
seasonal allergen exposure causes changes in the percent-
age and immunological status of T cell subsets in patients 
with allergic respiratory syndrome. To further character-
ize activation of T cells in this condition, production of 
cytokines by these cells was assessed.
Methods
Study group
Sixteen adult patients with at least a 1 year-long history 
of pollen allergy manifested by allergic rhinitis or atopic 
asthma were recruited into the study (Table  1). Allergy 
was previously confirmed by skin prick tests and by the 
presence of specific IgE. Patients involved in the study 
did not present with symptoms at the beginning of the 
study. If patients suffered from asthma, the disease had to 
be well controlled prior to participation in the study. At 
the beginning of the observation, patients were not tak-
ing any antihistamines, although they were permitted to 
use inhaled glucocorticosteroids or inhaled β2-mimetics. 
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If a patient had been taking antihistamines prior to the 
study, treatment was discontinued for at least 2 months 
before the beginning of observations.
Patients with symptoms of perennial allergy or with 
concomitant allergy to other seasonal allergens with 
overlapping time of symptom occurrence were excluded 
from the study. Those suffering from chronic or inflam-
matory diseases or undergoing immunotherapy within 
the past 3 years were also excluded.
Blood samples were collected three times from all 
patients within 1 year: before allergy season (visit 1), dur-
ing allergy season immediately following the appearance 
of symptoms (visit 2) and 2  weeks after the appearance 
of symptoms (visit 3). At the onset of symptoms (visit 2), 
after blood sample collection, all patients were started on 
treatment with new antihistamines. Treatment was dis-
continued after symptoms subsided.
In the period of high pollen concentration, blood sam-
ples collected from 16 healthy controls with no history 
of allergy, with negative skin prick tests for pollens, not 
taking steroids, antihistamines, β2-mimetic nor mon-
telukast, were also examined (Table  1). Investigation 
protocol was approved by the Jagiellonian University Bio-
ethics Committee, Cracow, Poland (KBET/249/B/2012). 
Written consent was obtained from all subjects prior to 
enrollment in the study.
Blood sample collection
Blood samples were collected from patients into ethylen-
ediaminetetraacetic acid (EDTA) tubes. Whole blood was 
centrifuged to separate plasma, then peripheral blood 
mononuclear cells (PBMC) were isolated from the blood 
by standard gradient centrifugation on Lymphocyte Sep-
aration Medium (LSM) 1077 (PAA Laboratories GmbH, 
Austria).
Staining protocol
Isolated cells were washed twice with a solution of phos-
phate-buffered saline (PBS) with 1  % heat inactivated 
fetal bovine serum (FBS) from Gibco (Life Technolo-
gies, USA) and suspended in this buffer. The amount of 
PBMC was estimated using a Fuchs-Rosenthal chamber. 
5 ×  105 cells were stained with monoclonal antibodies: 
anti-CD3–PerCP (Clone SK7), anti-CD4–APC (Clone 
SK3), anti-CD8–APC-H7 (Clone SK1), anti-CD45 RO–
PE (Clone UCHL1), anti-CD45 RA–FITC (Clone L48), 
anti-CCR7(CD197)–PE-Cy7 (Clone 3D12) from BD Bio-
sciences (San Jose, CA, USA). After staining for 20 min 
in the dark at 4 °C, cells were washed with PBS+ 1 %FBS 
and suspended in 200  μl of this buffer. These prepared 
cells were collected using a FACS Canto II flow cytom-
eter from BD Biosciences (San Jose, CA, USA). Data were 
analyzed using Flow Jo v10 (Ashland, OR, USA). First, 
lymphocytes were gated based on forward-scattered and 
side-scattered light (FSC/SSC). Next, the population of 
CD3+ cells (T cells) was selected. Among this group, 
subpopulations of CD4+ and CD8+ T cells were sepa-
rated (Additional file 1: Fig. S1a). On CD3+, CD4+ and 
CD8+ cells presence of CD45RA and CD45RO marker 
was assessed. T cell subpopulations were also analyzed 
for presence of naïve (CD45RA+ CCR7+), central mem-
ory (CD45RA−CCR7+), effector memory (CD45RA−
CCR7−) and CD45RA+ effector (CD45RA+ CCR7−) 
cells.
Assessment of intracellular cytokines
1 × 106 PBMC were suspended in RPMI 1600 medium 
(Gibco, Life Technologies, USA) with 10  % FBS, 
200 mM l-glutamine and 5 mg/ml gentamicin (Sigma–
Aldrich, Saint Louis, MO, USA) and cultured with 
Table 1 Clinical characteristics of  the patients and  a con-
trol group
Age and specific IgE levels are shown as mean ± SD, other features as number 
of patients
Comorbidity of seasonal allergic rhinitis and asthma was observed in 9 
individuals
Coexistence of allergy for tree and grass pollen was observed in 9 patients
Patient characteristics Experimental 
group
Control group
Age 31.8 ± 12.1 31.2 ± 5.3
Sex M:9; F:7 M:9; F:7
Disease
Allergic rhinitis 15 (93.8 %) 0
Asthma 10 (62.5 %) 0
Allergic conjunctivitis 14 (87.5 %) 0
Atopic dermatitis 1 (6.25 %) 0
Skin prick test positivity
Alder 13 (81.3 %) 0
Hazel 13 (81.3 %) 0
Birch 12 (75.0 %) 0
Grass 11 (68.8 %) 0
Specific IgE level for skin prick test—positive patients [IU/l]
Alder 15.3 ± 19.7 N.A.
Hazel 5.5 ± 7.5 N.A.
Birch 56.0 ± 39.2 N.A.
Grass 43.1 ± 46.4 N.A.
Specific IgE level for domi-
nant allergen [IU/l]
41.0 ± 43.7 N.A.
Currently smoking 2 (12.5 %) 1 (6.25 %)
Treatment
Inhaled steroid 7 (43.8 %) 0
Short acting β2‑mimetic 2 (12.5 %) 0
Montelukast 2 (12.5 %) 0
Long acting β2‑mimetic 1 (6.25 %) 0
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Leukocyte Activation Cocktail with BD Golgi Plug from 
BD Biosciences (San Jose, CA, USA) for 4 h at 37 °C in 
a 5 % CO2 humidified atmosphere. After this time, cells 
were washed with PBS+ 1 %FBS and stained with mono-
clonal antibodies anti-CD3–PerCP (Clone SK7), anti-
CD4–APC (Clone RPA-T4), anti-CD8–APC-H7 (Clone 
SK1) from BD Biosciences (San Jose, CA, USA). Next, 
cells were washed with PBS+ 1  %FBS and suspended 
in Fixation/Permeabilization Solution (BD Biosciences, 
San Diego, CA, USA). After permeabilization, cells were 
washed with Perm/Wash/Buffer (BD Biosciences, San 
Diego, CA, USA) and stained with monoclonal anti-
bodies: anti-IFNγ–FITC (Clone B27), anti-IL-17A–PE 
(Clone N49-653), anti-TNF–FITC (Clone MAb11) and 
anti-IL-4–PE (Clone 8D4-8). In some cases, isotype 
controls: IgG1 κ–FITC (Clone MOPC-21) for IFNγ 
and TNF, IgG1κ–PE (Clone MOPC-21) for IL-17A and 
IL-4 were used (BD Biosciences, San Jose, CA, USA). 
All staining and permeabilization were performed for 
20  min in the dark at 4  °C. After intracellular staining, 
cells were washed with Perm/Wash Buffer, suspended in 
PBS+ 1 %FBS and collected using a FACS Canto II flow 
cytometer from BD Biosciences (San Jose, CA, USA).
Statistics
The Shapiro–Wilk test was used to test normality of dis-
tribution of all analyzed variables. Repeated measures 
ANOVA was used to test the difference in specific T 
lymphocyte subpopulations between three visits stud-
ied. Subpopulations that significantly differed between 
three visits were further chosen for paired tests, compar-
ing two visits as well as tests comparing a single visit of 
study and control groups using t test. All tests were per-
formed in IBM SPSS Statistics (ver. 23). Results are pre-
sented as mean ± SEM. P values <0.05 were considered 
as significant.
Results
Intracellular cytokine production
Influence of seasonal allergen exposure on cytokine pro-
duction was assessed by intracellular staining of IL-4, 
TNF, IFNγ and IL-17A. A significant increase in IL-4 was 
observed in CD4+ cells during pollen season (1.0 vs 2.1 
vs 2.0 %) (Fig. 1a). There were no changes in the percent-
ages of TNF+ nor IFNγ+ T cells during the visits (Fig. 1a 
and b). IL-17A was produced by CD4 cells in very small 
amounts and did not change significantly during pollen 
season (Fig. 1a).
CD 45RA/RO
Next, to ascertain activation of the immune system 
caused by seasonal allergens, expression of CD45RA 
and CD45RO markers in CD4+ and CD8+ cells was 
investigated (Fig. 2a). The percentage of CD4+ CD45RA 
positive cells increased in allergic patients during pol-
len season from 40.8 % at the beginning of pollen season 
to 43.7  % 2  weeks after onset of symptoms (P  =  0.03) 
(Fig. 2b). Among CD8 cells, a decrease in transient cells 
during pollen season was observed at the beginning of 
pollen season (15.0  %) and 2  weeks from the onset of 
symptoms (15.5  %) in comparison to before pollen sea-
son (17.7 %) (V1–V2 P = 0.01; V1–V3 P = 0.03) (Fig. 1c). 
In all three groups, an increase in the percentage of 
CD45RO cells at the beginning of pollen season with a 
decrease 2  weeks later was observed, although only in 
CD3 cells this trend reached statistical significance (V1—
32.8 % vs V2—35.1 % vs V3—32.1 %; P respectively 0.01 
and 0.004) (data not shown). There were no differences in 
the percentage of CD45RA and CD45RO cells between 
allergic patents and the control group.
Memory Cell Subsets
To investigate the influence of allergen exposure on mem-
ory cell subsets we determined percentages of naïve, cen-
tral memory, effector memory and CD45RA+ effector 
cells in the group of CD4 and CD8 cells. Allergen expo-
sure did not cause statistically significant changes in the 
group of CD4 memory cells in pollen-sensitive patients, 
although an increase in the percentage of CD45RA+ 
effector cells 2  weeks after the onset of symptoms was 
close to statistical significance (ANOVA P = 0.06) (Fig. 3a 
and b). In the group of CD8 cells, a decrease in the per-
centage of central memory cells was observed during 
allergen exposure in comparison to the state before pollen 
season (10.1 vs 8.8 vs 9.1 % P = 0.01) (Fig. 4a and b).
T cell subsets
We also determined whether allergen exposure could 
influence the percentage of T cells. There were no statis-
tically significant differences observed among percent-
ages of CD4+ and CD8+ neither between visits nor in 
comparison with the control group (Additional file  1: 
Fig. S1b). The CD4/CD8 ratio also remained constant in 
allergic patients before and in the allergy season and did 
not differ from the control group.
Discussion
With regard to the increasing number of people suffering 
from allergies, understanding the mechanisms leading to 
the complex manifestation of symptoms is important in 
the search for effective treatment methods. As expected, 
coexistence of seasonal allergic rhinitis and asthma was 
observed in more than half of the individuals. Determi-
nation of the role of T cells and their subsets in seasonal 
allergy may be crucial to understanding the mechanism 
of this reaction.
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Natural allergen exposure caused a significant increase 
in IL-4 production by CD4 cells in pollen-sensitive 
patients. Our findings confirm the previous observa-
tion by Wosinska-Becler et  al. describing an increase of 
IL-4 during the peak of birch season in comparison with 
non-pollen season in birch-sensitive patients [21]. In 
this group of patients a decrease in IFNγ production in 
comparison with alder season was observed, but no sig-
nificant changes were present when compared with non-
pollen season, which is also consistent with our results. 
A study performed in asthmatic children revealed that 
the percentage of CD4+ cells producing IL-4 and cells 
producing IFNγ is higher during acute exacerbations 
than at convalescence [22]. Another study in children 
with atopic asthma showed an increase in the percent-
age of CD4 and CD8 cells producing IL-4 and a decrease 
in CD4 cells producing IFNγ in comparison with healthy 
controls, while the percentage of cells producing TNF 
remained unchanged [23]. In addition, the percentage 
of CD8 cells producing IL-4 spontaneously was higher 
in children with asthma in this study. Two other studies 
comparing patients with asthma and healthy controls did 
not demonstrate any changes in the percentage of cells 
producing IL-4. One of these studies reported a lower 
percentage of CD4 cells producing IFNγ in these patients 
[24], while the second study observed a higher percent-
age of CD4 and CD8 cells producing IFNγ in atopic 
asthmatic patients [25]. Bias of results showing changes 
in patients suffering from allergic asthma can be related 
to the various kinds of allergens that they were sensitive 
to (i.e. house dust, animals, moulds), while in our study 
exposition to seasonal allergen was investigated.
Allergen provocation outside of pollen season in 
patients with asthma resulted in a decrease in IL-4+ 
CD4+ cells. In this study, changes in the number of 
IFNγ-producing CD4 cells depended on response type. 
A decrease in IFNγ-producing CD4 cells was observed 
in patients who presented only with early reaction to the 
allergen challenge, without late-phase reaction [26].
Some studies report an increased percentage of Th17 
cells in patients with allergic rhinitis. However, in most 
of these studies, patients allergic to perennial allergens 
[27, 28] or sensitive to seasonal and perennial allergens 
were involved [29]. Another study describes the influence 
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Fig. 1 Changes in intracellular cytokine production in T cell subsets during pollen season. Isolated PBMCs were stimulated with leukocyte activa‑
tion cocktail and were cultured for 4 h. After this time, intracellular production of cytokines was detected in CD4+ T cells (a) and in CD8+ T cells 
(b). IL‑4 positive or IL‑17A positive T cells (a) and IFNγ positive or TNF positive T cells (a and b) are shown. V1—before allergy season, V2—during 
allergy season immediately following the appearance of symptoms, V3—2 weeks after onset of symptoms, CTRL—control group; data are shown 
as mean ± SEM; *P < 0.05  in paired samples t test; #P < 0.05 in unpaired samples t test; $P < 0.05 in repeated measures ANOVA, testing all three 
patients’ visits. Comparisons of cell populations for pairs of single patients’ visits were performed using paired samples t test, while comparisons of 
cell populations between single patients visit and control subjects were performed using unpaired samples t test
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of perennial allergen challenge by nebulization on Th17 
cells [30], however, less is known about changes over 
time caused by natural seasonal allergen exposure. It was 
shown that the percentage of IL-17A-producing CD4+ T 
cells may also depend on polysensitization of the patients 
and on patient’s sex [29]. Although an increased serum 
IL-17 level was observed in patients sensitive to peren-
nial allergens, pollen allergens did not cause significant 
changes [29].
In our study, we did not observe significant changes in 
the intracellular production of this cytokine. Our results 
are in opposition to Ciprandi et al. who describe a higher 
percentage of Th17 cells in pollen-sensitive allergic rhi-
nitis patients than in the healthy controls, however, the 
control group in this study was very small and compari-
son to the state before pollen season was not performed 
[31].
Our findings demonstrate the influence of pollen sea-
son on memory cells in patients suffering from allergic 
respiratory syndrome. We did not observe any changes 
in CD4+ nor CD8+ T cells caused by natural allergen 
exposure. Our results are consistent with those of Kalrs-
son et al. who have shown an increase in CD4+ cells in 
patients suffering from allergic rhinitis during provoca-
tion but not during natural antigen exposure [32]. After 
in vitro stimulation with P. pratense, an increased num-
ber of circulating allergen-specific CD4+ T cells was 
seen. In addition, proliferation of CD4+ cells and in some 
cases, CD8+ cells was observed in grass pollen allergic 
patients [33]. In pollen-sensitive patients receptor density 
also changes throughout the year. In these individuals, 
Monteseirin et al. observed a decrease in the number of 
CD4+ receptors per cell in the spring [34].
Exposure to seasonal allergens affected expression of 
CD45 RA/RO isoforms in pollen-sensitive patients. We 
observed an increase in CD4+ CD45RA+ cells 2 weeks 
from the beginning of allergy season in comparison with 
the onset of symptoms. These changes were accompa-
nied by a decrease in transient CD8 cells during pol-
len season. Although presence of the CD45RA marker 
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Fig. 2 Changes in CD45RA and CD45RO subpopulations of T cell subsets during pollen season. Distribution of CD45RA and CD45RO marker 
among CD4+ cells (a and b) and CD8+ cells (a and c) was analyzed. Cytometric example 2 weeks after the onset of symptoms is shown in (a). V1—
before allergy season, V2—during allergy season immediately following the appearance of symptoms, V3—2 weeks after the onset of symptoms, 
CTRL—control group; data are shown as mean ± SEM; *P < 0.05 in paired samples t test; $P < 0.05 in repeated measures ANOVA, testing all three 
patients’ visits. Comparisons of cell populations for pairs of single patients’ visits were performed using paired samples t test, while comparisons of 
cell populations between single patients visit and control subjects were performed using unpaired samples t test
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is characteristic for naïve cells and CD45RO maker for 
memory cells, re-call antigen stimulated change of CD4 
cells from RA+ to RO+ phenotype is a gradual process 
during which two transitional subsets co-expressing RA 
and RO are present: CD45RAbright/RObright, which are 
present in very small amount, and CD45RAdull/ROdull 
expressing both isoforms at low level, possessing mixed 
features of CD45RA+ and CD45RO+ cells. Moreover, 
CD45RO+ cells under certain conditions can re-acquire 
the RA marker [35]. Cells co-expressing CD45RA and 
CD45RO have been described in patients with atopic 
asthma, and these subsets form 31–46 % of the T helper 
cells [36]. In our study transient cells formed on aver-
age, depending on visit, 15.7–16.6  % of CD4 cells and 
15.0–17.7  % of CD8 cells in allergen-sensitive patients 
and did not differ from the control group. In children 
with allergic asthma an increase in the absolute number 
of CD8+ T cells expressing CD45RO is associated with 
a decrease in percentage, but not in the absolute num-
ber of CD4+ CD45RO positive cells when compared 
with healthy controls [37]. We did not observe any dif-
ferences in the percentage of CD4 and CD8 RO positive 
cells between allergic patients and the control group. 
Although we have seen an increase in CD3 cells express-
ing CD45RO marker at the beginning of allergen season 
with a decrease 2  weeks later, these changes were not 
significant either on CD4 or CD8 cells. Similar findings, 
representing transformation of lymphocytes from naïve 
into memory type cells caused by contact with allergen, 
were described previously by Pawlik et al. on CD4 cells, 
who however, observed an increase in CD4+ 45RO+ 
lymphocytes in the blood of patients with seasonal 
symptoms during allergy season [38]. A decrease in the 
percentage of CD3+ CD45RO+ cells two weeks after 
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the onset of symptoms in our study can be explained 
by migration of CD45RO+ cells into the inflammatory 
site [39]. The mechanisms of this process are complex 
and may include various factors such as oxidative stress, 
which lead to inflammation [40].
Investigation of skin biopsies obtained from pollen-
allergic patients challenged with intradermal injection of 
allergen demonstrated increased frequency of memory 
cells 24 h after challenge in comparison with stimulation 
with control solution, suggesting a role for these cells in 
the cutaneous late-phase reaction [41]. Immunocyto-
chemical analysis of nasal mucosa of patients suffering 
from seasonal allergic rhinitis revealed an increase in 
CD4+ CD45RO+ cells during pollen season [42]. The 
presence of activated memory T cells in mucosa was also 
demonstrated using flow cytometry, however, there were 
no differences between allergic and non-allergic patients. 
Moreover, these findings were present only at the inflam-
matory site and did not correlate with peripheral blood 
mononuclear cells [43].
A recent study demonstrated an increased number of 
effector/memory T cells (CD4+CD25low) in patients 
with seasonal allergic rhinitis 6  h after nasal allergen 
challenge with grass pollen. This study described changes 
in peripheral blood cells, although allergen challenge was 
induced only once and may not have accurately reflected 
the changes caused by natural exposure during allergy 
season [44]. In patients with allergic rhinitis, the response 
to provocational exposure may be different from the 
response during pollen season [32].
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We observed a decrease in CD8 central memory cells 
during pollen season. These changes reflect the differ-
entiation of memory cells in the allergic reaction, with 
CD45RA+ effector cells being the most differentiated 
type. A non-significant increase in CD45RA+ effector 
cell subpopulation of CD4 cells appears 2 weeks after the 
first presentation of symptoms (visit 3) when compared 
with the measurement performed at the onset of symp-
toms (visit 2). This is probably due to the time needed 
to convert effector memory cells into CD45RA+ effec-
tor cells. In this period of time all patients were receiving 
treatment with new antihistamines, which were shown 
to be highly effective in relieving symptoms of seasonal 
allergic rhinitis [45, 46]. This medication was not admin-
istered during the previous visit (at the onset of symp-
toms) and could have also affected our results. Although 
the influence of H2-blockers on CD4+ RO+ cells and 
suppressor cells was previously demonstrated [19], less 
is known about the influence of new H1-blockers on 
these cells. However, the effect of the first generation 
H1-blocker, clemastine, on natural killer and antibody-
dependent cellular cytotoxicity activities of lymphocytes 
have been described [47].
Conclusions
In summary, our data shows that natural seasonal aller-
gen exposure in patients with allergic respiratory syn-
drome affects T cell activation and their memory status, 
without altering Th1 and Th17 responses. Additional 
studies are required to better understand the complexity 
of cellular reactions in patients with allergic respiratory 
syndrome.
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